Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 3
2018 2
2019 3
2020 1
2021 2
2022 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Altwegg KA, Viswanadhapalli S, Mann M, Chakravarty D, Krishnan S, Liu Z, Liu J, Pratap UP, Ebrahimi B, Sanchez JR, Li X, Ma S, Park BH, Santhamma B, Chen Y, Lai Z, Raj GV, Yuan Y, Zhou D, Sareddy GR, Tekmal RR, McHardy S, Huang TH, Rao MK, Vankayalapati H, Vadlamudi RK. Altwegg KA, et al. Cancer Res. 2022 Oct 17;82(20):3830-3844. doi: 10.1158/0008-5472.CAN-22-0698. Cancer Res. 2022. PMID: 35950923 Free PMC article.
Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress.
Liu X, Viswanadhapalli S, Kumar S, Lee TK, Moore A, Ma S, Chen L, Hsieh M, Li M, Sareddy GR, Parra K, Blatt EB, Reese TC, Zhao Y, Chang A, Yan H, Xu Z, Pratap UP, Liu Z, Roggero CM, Tan Z, Weintraub ST, Peng Y, Tekmal RR, Arteaga CL, Lippincott-Schwartz J, Vadlamudi RK, Ahn JM, Raj GV. Liu X, et al. Nat Cancer. 2022 Jul;3(7):866-884. doi: 10.1038/s43018-022-00389-8. Epub 2022 Jun 2. Nat Cancer. 2022. PMID: 35654861 Free PMC article.
Targeting aberrant replication and DNA repair events for treating breast cancers.
Rajamanickam S, Park JH, Subbarayalu P, Timilsina S, Bates K, Yadav P, Nirzhor SSR, Eedunuri V, Mohammad TA, Jung KH, Onyeagucha B, Abdelfattah N, Benevides R, Lee G, Chen Y, Vadlamudi R, Brenner A, Kaklamani V, Jatoi I, Kuhn J, Hromas R, Gupta YK, Kaipparettu BA, Arbiser JL, Rao MK. Rajamanickam S, et al. Commun Biol. 2022 May 24;5(1):493. doi: 10.1038/s42003-022-03413-w. Commun Biol. 2022. PMID: 35610507 Free PMC article.
EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.
Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Ma S, Sonavane R, Pratap UP, Altwegg KA, Li X, Chang A, Chávez-Riveros A, Dileep KV, Zhang KYJ, Pan X, Murali R, Bajda M, Raj GV, Brenner AJ, Manthati V, Rao MK, Tekmal RR, Nair HB, Nickisch KJ, Vadlamudi RK. Viswanadhapalli S, et al. Mol Cancer Ther. 2019 Aug;18(8):1341-1354. doi: 10.1158/1535-7163.MCT-18-1258. Epub 2019 May 29. Mol Cancer Ther. 2019. PMID: 31142661 Free PMC article.
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
Viswanadhapalli S, Ma S, Sareddy GR, Lee TK, Li M, Gilbreath C, Liu X, Luo Y, Pratap UP, Zhou M, Blatt EB, Kassees K, Arteaga C, Alluri P, Rao M, Weintraub ST, Tekmal RR, Ahn JM, Raj GV, Vadlamudi RK. Viswanadhapalli S, et al. Breast Cancer Res. 2019 Dec 26;21(1):150. doi: 10.1186/s13058-019-1227-8. Breast Cancer Res. 2019. PMID: 31878959 Free PMC article.
17 results